Trial Profile
First line trastuzumab- or lapatinib-based therapy in her2-positive metastatic breast cancer patients after prior (neo)adjuvant trastuzumab
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 25 Jan 2016
Price :
$35
*
At a glance
- Drugs Lapatinib (Primary) ; Trastuzumab (Primary)
- Indications Breast cancer
- Focus Therapeutic Use
- 25 Jan 2016 New trial record